What is Medical Developments International PB Ratio?
Medical Developments InternationalASX:MVP +1.30%57 PB Ratio is 0.80 as of Jun. 28, 2026, which is 86% below its 10-year median of 5.85. GuruFocus rates ASX:MVP with a GF Score™ of 57/100 and a GF Value™ of A$0.65 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Medical Developments International ranks better than 82.23% on this metric.
ASX:MVP'
s PB Ratio Range Over the Past 10 Years
Min: 0.42 Med: 5.85 Max: 21.79
Current: 0.8
During the past 13 years, Medical Developments International's highest PB Ratio was 21.79. The lowest was 0.42. And the median was 5.85.
ASX:MVP's PB Ratio is ranked better than 82.23% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.81
vs ASX:MVP: 0.80
During the past 12 months, Medical Developments International's average Book Value Per Share Growth Rate was -1.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -14.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -7.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Medical Developments International was 39.20% per year. The lowest was -17.50% per year. And the median was 9.05% per year.
Back to Basics: PB Ratio
Medical Developments International (ASX:MVP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Medical Developments International PB Ratio Related Terms
Medical Developments International PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medical Developments International's PB Ratio falls into.
Medical Developments International PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medical Developments International (ASX:MVP) has a PB Ratio of 0.80 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medical Developments International and its competitors. This is 86% below median its historical median of 5.85. Over the past decade, Medical Developments International's PB Ratio has ranged from 0.42 to 21.79. According to the industry distribution chart, Medical Developments International ranks #164 out of 923 companies in the Drug Manufacturers industry, placing it in the top 17.8%.
Is Medical Developments International's PB Ratio too high?
Medical Developments International's current PB Ratio of 0.80 is 86% below median its 10-year median of 5.85. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 21.79. The Drug Manufacturers industry median PB Ratio is 1.81. Medical Developments International's value of 0.80 is 55.8% below this industry median. Based on the distribution chart, Medical Developments International ranks #164 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medical Developments International has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #164 out of 923 companies for PB Ratio. This places Medical Developments International in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.81. Medical Developments International's value of 0.80 is 55.8% below this benchmark. Historically, Medical Developments International's own PB Ratio has ranged from 0.42 to 21.79 over the past decade. While the company's 10-year median is 5.85 vs. the industry median of 1.81, Medical Developments International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.81, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current PB Ratio of 0.80 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current PB Ratio is 0.80, which is 86% below median its own 10-year median of 5.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.65, compared to a current price of A$0.39 — trading 40% below its estimated fair value. The current PB Ratio is 0.80, which is 86% below median its 10-year median of 5.85 and 55.8% below the Drug Manufacturers industry median of 1.81. Medical Developments International's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current PB Ratio is 0.80 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.39 is trading 40% below its estimated GF Value™ of A$0.65.
GuruFocus considers Medical Developments International to be Significantly Undervalued.
Key valuation signals for ASX:MVP:
PB Ratio: 0.80 (86% below median its 10-year median of 5.85)
GF Value™: A$0.65 vs. price of A$0.39 (40% below fair value)
Industry Position: 55.8% below the Drug Manufacturers median (#164 of 923)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
57GF Score
Get the complete analysis for ASX:MVP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
